Description

The data presented in the Vaccine Tracker are submitted by European Union/European Economic Area (EU/EEA) countries to ECDC through The European Surveillance System (TESSy) once every two weeks on Tuesdays. EU/EEA countries report aggregated data on the number of vaccine doses distributed by manufacturers to the country, the number of first, second, additional and unspecified doses administered to adults (18+), adolescent and children (<18) overall, by age groups and in specific target groups, such as healthcare workers (HCWs) and in residents in long-term care facilities (LTCFs). Doses are also reported by vaccine product.

The downloadable data files contain the data on the COVID-19 vaccine rollout mentioned above and each row contains the corresponding data for a certain week and country. The files are updated once every two weeks on Thursdays. Data are subject to retrospective corrections; corrected datasets are released as soon as processing of updated national data has been completed. You may use the data in line with ECDC's <u>copyright policy</u>.

Data dictionary

Variable	Definition	Code
YearWeekISO	Date when the vaccine was received/administered. Only weeks are allowed (e.g. "2021-W01").	yyyy-Www
ReportingCountry	ISO 3166-1-alpha-2	two-letter code
Denominator	Population denominators for target groups (total population and age- specific population obtained from Eurostat/UN). Denominators reported by countries for TargetGroup = "LTCF".	Numeric
NumberDosesRec eived	Number of vaccine doses distributed by the manufacturers to the country during the reporting week.	Numeric
NumberDosesExp orted	Number of vaccine doses donated or sold by the country during the reporting week.	Numeric
FirstDose	Number of first dose vaccine administered to individuals during the reporting week.	Numeric
FirstDoseRefused	Number of individuals refusing the first vaccine dose.	Numeric
SecondDose	Number of second dose vaccine administered to individuals during the reporting week.	Numeric

ECDC NORMAL

DoseAdditional1	Number of first additional vaccine	Numeric
	doses administered after a	
	complete standard primary course	
	to individuals during the reporting	
	week.	
DoseAdditional2	Number of second additional	Numeric
	vaccine doses administered after a	
	complete standard primary course	
	to individuals during the reporting	
D = = = A = = = = = 2	week. Number of third additional vaccine	Niversita
DoseAdditional3	doses administered after a	Numeric
	complete standard primary course	
	to individuals during the reporting	
	week.	
DoseUnk	Number of doses administered	Numeric
	during the reporting week where	
	the type of dose was not	
	specified (i.e. it is not known	
	whether it was a first or second	
	dose).	
Region	As a minimum data should be	Country/NUTS1 or 2/GAUL1/Country
	reported at national level	specific
	(Region = country code).	
TargetGroup	Target group for vaccination.	ALL = Overall adults (18+)
l angerer ap		Age<18 = Overall adolescents and children (0-
		17 years old)
		HCW = Healthcare workers
		LTCF = Residents in long term care facilities
		AgeO_4 = 0-4 years old
		Age5_9 = 5-9 years old
		Age10_14 = 10-14 years old
		Age15_17 = 15-17 years old Age18_24 = 18-24 years old
		Age25 $49 = 25-49$ years old
		Age50_59 = 50-59 years old
		Age60_69 = 60-69 years old
		Age70_79 = 70-79 years old
		Age80+ = 80 years and over
		AgeUnk = Unknown age
		1_Age<60 = adults below 60 years of age
		and above 17
Vaccine name	Name of consider Additional	1_Age60+ = adults 60 years and over AZ = AstraZeneca - Vaxzevria
vaccine name	Ivallie of vaccine. Additional	BECNBG = Beijing CNBG - BBIBP-CorV
	vaccines will be daded on	BHACOV = Bharat - Covaxin
	approvaror as requested.	CHU = Chumakov - Covi-Vac
		CAN = CanSino - Convidecia
		COM = Pfizer BioNTech - Comirnaty

		COMBA.1= Pfizer BioNTech - Comirnaty
		Original/Omicron BA.1
		COMBA.4-5 = Pfizer BioNTech – Comirnaty
		Original/Omicron BA.4/BA.5
		COMBIV = Pfizer BioNTech – Comirnaty
		(Original/Omicron BA.1 or Original/Omicron
		BA.4/BA.5)
		CVAC = Curevac - CVnCOV
		HAYATVAC = Julphar- Hayat-Vax
		JANSS = Janssen - Jcovden
		MOD = Moderna - Spikevax
		MODBA.1 = Moderna - Spikevax Bivalent
		Original/Omicron BA.1
		MODBA.4-5 = Moderna - Spikevax Bivalent
		Original/Omicron BA.4/BA.5
		MODBIV = Moderna - Spikevax Bivalent
		(Original/Omicron BA.1 or Original/Omicron
		BA.4/BA.5)
		NVX = SII – Covovax
		NVXD = Novavax – Nuvaxovid
		QAZVAQ = RIBSP - QazVac
		SGSK = Sanofi GSK - Vidprevtyn
		SIICOV = SII - Covishield
		SIN = Sinovac - CoronaVac
		SPU = Gamaleya - Sputnik-V
		SPUL = Gamaleya - Sputnik-Light
		SRCVB = SRCVB - EpiVacCorona
		UNK = UNKNOWN
		VLA = Valneva – VLA2001
		WUCNBG = Wuhan CNBG - Inactivated
		ZFUZ = Anhui ZL - Zifivax
Population	Age-specific population for the	Numeric
	country	

Definitions

- **Healthcare workers (HCW):** refer to those who work in healthcare settings who may come into contact with patients, including clinical administration staff, and home care staff.
- **Doses of vaccines:** refers to the total number of vaccine doses, considering that an additional dose may be obtained from each vial (e.g. six doses for Pfizer BioNTech® Comirnaty).
- Number of doses distributed refers to the doses distributed by the manufacturers to the country.
- Number of doses administered refers to any individual receiving any dose of the vaccine.
- Additional dose and boosters refer to doses administered after a complete primary course, being them administered respectively as an extension of the primary course (e.g. in moderately to severely immunocompromised individuals) or as boosters in individuals who already received a standard primary course (e.g. see footnote with WHO definitions¹).

¹ Definitions and terminology used by WHO throughout its policy recommendations on COVID-19 vaccination

• Weekly data refer to:

- Week of vaccine distribution by the manufacturers to the country
- Week of vaccine dose administration to individuals receiving any of the first, second, additional or unspecified dose

⁽https://www.who.int/news/item/04-10-2021-interim-statement-on-booster-doses-for-covid-19-vaccination):

[•] Booster doses are administered to a vaccinated population that has completed a primary vaccination series (currently one or two doses of COVID-19 vaccine depending on the product) when, with time, the immunity and clinical protection has fallen below a rate deemed sufficient in that population. The objective of a booster dose is to restore vaccine effectiveness from that deemed no longer sufficient.

[•] Additional doses of a vaccine may be needed as part of an extended primary series for target populations where the immune response rate following the standard primary series is deemed insufficient. The objective of an additional dose in the primary series is to optimize or enhance the immune response to establish a sufficient level of effectiveness against disease. In particular, immunocompromised individuals often fail to mount a protective immune response after a standard primary series, but also older adults may respond poorly to a standard primary series.